Download PDF
Semin Thromb Hemost 2016; 42(06): 682-688
DOI: 10.1055/s-0036-1571338
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Factor XII in Hemostasis and Thrombosis: Active Player or (Innocent) Bystander?

Elisa Danese
1   Section of Clinical Biochemistry, University of Verona, Verona, Italy
,
Martina Montagnana
1   Section of Clinical Biochemistry, University of Verona, Verona, Italy
,
Giuseppe Lippi
1   Section of Clinical Biochemistry, University of Verona, Verona, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
13 April 2016 (online)

    Permissions and Reprints

Abstract

Coagulation factor XII (FXII), formerly known as Hageman factor, is a plasma glycoprotein which exerts a kaleidoscope of biological functions, including the initiation of the intrinsic pathway of blood coagulation, the activation of the kallikrein-kinin system, and the generation of bradykinin and angiotensin. The large body of evidence accumulated over the past decades and the revised cell-based model of hemostasis suggest that FXII may be somehow “redundant” for physiological hemostasis, drawing a potential interpretation of this protein as a possible “innocent” bystander of in vivo hemostasis. Although the contribution of FXII remains unproven in the pathogenesis of venous thromboembolism, perhaps reinforcing this perception of “redundancy,” recent work identifies FXII as critical for initiation of thrombosis on artificial surfaces (e.g., polyurethanes or polytetrafluoroethylene catheters), or in patients with strong prothrombotic conditions such as vulnerable atherosclerotic plaques or severe bacterial infections. Important evidence has also emerged from recent investigations using innovative FXII inhibitors in ex vivo animal models, wherein targeted FXII-mediated inhibition of thrombin and fibrin generation may open new avenues for prevention or treatment of certain types of thrombosis. Thus, interest in FXII, waned in the recent past, is again re-emerging, and pointing to important but under-recognized contribution to in vivo hemostasis and thrombosis.

Keywords

hemostasis - thrombosis - blood coagulation - factor XII - anticoagulant therapy
 

  • References

  • 1 Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34 (4) 602-613
    CrossrefPubMedGoogle Scholar
  • 2 Cool DE, MacGillivray RTA. Characterization of the human blood coagulation factor XII gene. Intron/exon gene organization and analysis of the 5′-flanking region. J Biol Chem 1987; 262 (28) 13662-13673
    PubMedGoogle Scholar
  • 3 Farsetti A, Misiti S, Citarella F , et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 1995; 136 (11) 5076-5083
    CrossrefPubMedGoogle Scholar
  • 4 Inoue Y, Peters LL, Yim SH, Inoue J, Gonzalez FJ. Role of hepatocyte nuclear factor 4alpha in control of blood coagulation factor gene expression. J Mol Med (Berl) 2006; 84 (4) 334-344
    CrossrefPubMedGoogle Scholar
  • 5 Gordon EM, Gallagher CA, Johnson TR, Blossey BK, Ilan J. Hepatocytes express blood coagulation factor XII (Hageman factor). J Lab Clin Med 1990; 115 (4) 463-469
    PubMedGoogle Scholar
  • 6 Maas C, Govers-Riemslag JW, Bouma B , et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008; 118 (9) 3208-3218
    PubMedGoogle Scholar
  • 7 Stavrou E, Schmaier AH. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res 2010; 125 (3) 210-215
    CrossrefPubMedGoogle Scholar
  • 8 Dunn JT, Silverberg M, Kaplan AP. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem 1982; 257 (4) 1779-1784
    PubMedGoogle Scholar
  • 9 van der Meijden PE, Munnix IC, Auger JM , et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood 2009; 114 (4) 881-890
    CrossrefPubMedGoogle Scholar
  • 10 Puy C, Tucker EI, Wong ZC , et al. Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates. J Thromb Haemost 2013; 11 (7) 1341-1352
    CrossrefPubMedGoogle Scholar
  • 11 Zakharova NV, Artemenko EO, Podoplelova NA , et al. Platelet surface-associated activation and secretion-mediated inhibition of coagulation factor XII. PLoS ONE 2015; 10 (2) e0116665
    CrossrefPubMedGoogle Scholar
  • 12 Forbes CD, Pensky J, Ratnoff OD. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J Lab Clin Med 1970; 76 (5) 809-815
    PubMedGoogle Scholar
  • 13 MacQuarrie JL, Stafford AR, Yau JW , et al. Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation. Blood 2011; 117 (15) 4134-4141
    CrossrefPubMedGoogle Scholar
  • 14 Stead N, Kaplan AP, Rosenberg RD. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem 1976; 251 (21) 6481-6488
    PubMedGoogle Scholar
  • 15 Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C. In vivo roles of factor XII. Blood 2012; 120 (22) 4296-4303
    CrossrefPubMedGoogle Scholar
  • 16 Lippi G, Favaloro EJ. Laboratory hemostasis: milestones in Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med 2013; 51 (1) 91-97
    PubMedGoogle Scholar
  • 17 Lippi G, Franchini M, Guidi GC. Diagnostic approach to inherited bleeding disorders. Clin Chem Lab Med 2007; 45 (1) 2-12
    CrossrefPubMedGoogle Scholar
  • 18 de Maat S, de Groot PG, Maas C. Contact system activation on endothelial cells. Semin Thromb Hemost 2014; 40 (8) 887-894
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Renné T, Pozgajová M, Grüner S , et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202 (2) 271-281
    CrossrefPubMedGoogle Scholar
  • 20 Kleinschnitz C, Stoll G, Bendszus M , et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203 (3) 513-518
    CrossrefPubMedGoogle Scholar
  • 21 Cheng Q, Tucker EI, Pine MS , et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010; 116 (19) 3981-3989
    CrossrefPubMedGoogle Scholar
  • 22 Yau JW, Stafford AR, Liao P, Fredenburgh JC, Roberts R, Weitz JI. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood 2011; 118 (25) 6667-6674
    CrossrefPubMedGoogle Scholar
  • 23 Kuijpers MJ, van der Meijden PE, Feijge MA , et al. Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Arterioscler Thromb Vasc Biol 2014; 34 (8) 1674-1680
    CrossrefPubMedGoogle Scholar
  • 24 Cai TQ, Wu W, Shin MK , et al. Factor XII full and partial null in rat confers robust antithrombotic efficacy with no bleeding. Blood Coagul Fibrinolysis 2015; 26 (8) 893-902
    CrossrefPubMedGoogle Scholar
  • 25 Xu Y, Cai TQ, Castriota G , et al. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit. Thromb Haemost 2014; 111 (4) 694-704
    PubMedGoogle Scholar
  • 26 Matafonov A, Leung PY, Gailani AE , et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 2014; 123 (11) 1739-1746
    CrossrefPubMedGoogle Scholar
  • 27 Larsson M, Rayzman V, Nolte MW , et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014; 6 (222) 222ra17
    CrossrefPubMedGoogle Scholar
  • 28 Konings J, Hoving LR, Ariëns RS , et al. The role of activated coagulation factor XII in overall clot stability and fibrinolysis. Thromb Res 2015; 136 (2) 474-480
    CrossrefPubMedGoogle Scholar
  • 29 Lippi G, Favaloro EJ. Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost 2008; 34 (7) 604-611
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Lippi G, Franchini M, Brazzarola P, Manzato F. Preoperative screening: the rationale of measuring APTT in risk assessment. Haematologica 2001; 86 (3) 328
    PubMedGoogle Scholar
  • 31 Houlihan LM, Davies G, Tenesa A , et al. Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time. Am J Hum Genet 2010; 86 (4) 626-631
    CrossrefPubMedGoogle Scholar
  • 32 Gallimore MJ, Jones DW, Wendel HP. A chromogenic substrate assay kit for factor XII: evaluation and use for the measurement of factor XII levels in cardiopulmonary bypass patients. Thromb Res 1999; 94 (2) 103-109
    CrossrefPubMedGoogle Scholar
  • 33 Madsen DE, Sidelmann JJ, Overgaard K, Koch C, Gram JB. ELISA for determination of total coagulation factor XII concentration in human plasma. J Immunol Methods 2013; 394 (1–2) 32-39
    CrossrefPubMedGoogle Scholar
  • 34 Lippi G, Pasalic L, Favaloro EJ. Detection of mild inherited disorders of blood coagulation: current options and personal recommendations. Expert Rev Hematol 2015; 8 (4) 527-542
    CrossrefPubMedGoogle Scholar
  • 35 Renné T, Gailani D. Role of Factor XII in hemostasis and thrombosis: clinical implications. Expert Rev Cardiovasc Ther 2007; 5 (4) 733-741
    CrossrefPubMedGoogle Scholar
  • 36 Lämmle B, Wuillemin WA, Huber I , et al. Thromboembolism and bleeding tendency in congenital factor XII deficiency—a study on 74 subjects from 14 Swiss families. Thromb Haemost 1991; 65 (2) 117-121
    PubMedGoogle Scholar
  • 37 Zeerleder S, Schloesser M, Redondo M , et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency—a study on 73 subjects from 14 Swiss families. Thromb Haemost 1999; 82 (4) 1240-1246
    PubMedGoogle Scholar
  • 38 Koster T, Rosendaal FR, Briët E, Vandenbroucke JP. John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia Study. Br J Haematol 1994; 87 (2) 422-424
    CrossrefPubMedGoogle Scholar
  • 39 Hagedorn I, Schmidbauer S, Pleines I , et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010; 121 (13) 1510-1517
    CrossrefPubMedGoogle Scholar
  • 40 Müller F, Gailani D, Renné T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol 2011; 18 (5) 349-355
    CrossrefPubMedGoogle Scholar
  • 41 Girolami A, Ruzzon E, Lombardi AM, Cabrio L, Randi ML. Thrombosis-free surgical procedures in severe (Homozygote) factor XII deficiency: report of four additional cases and literature review. Clin Appl Thromb Hemost 2004; 10 (4) 351-355
    CrossrefPubMedGoogle Scholar
  • 42 Nicholls J, Chan LC, Koo YM, Kwong YL, Tsoi NS. Subdural haematoma and factor XII deficiency in a Chinese infant. Injury 1993; 24 (3) 202-203
    CrossrefPubMedGoogle Scholar
  • 43 Kaspera W, Rothkegel K, Stadnicki A. Subdural hematoma in a patient with Hageman trait—case report. Neurol Med Chir (Tokyo) 2005; 45 (12) 640-644
    CrossrefPubMedGoogle Scholar
  • 44 Oh JY, Khwarg SI. Orbital subperiosteal hemorrhage in a patient with factor VIII and factor XII Deficiency. J Pediatr Ophthalmol Strabismus 2004; 41 (6) 367-368
    PubMedGoogle Scholar
  • 45 Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 1992; 68 (3) 285-290
    PubMedGoogle Scholar
  • 46 von Känel R, Wuillemin WA, Furlan M, Lämmle B. Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagul Fibrinolysis 1992; 3 (5) 555-561
    CrossrefPubMedGoogle Scholar
  • 47 Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F. The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J Thromb Thrombolysis 2004; 17 (2) 139-143
    CrossrefPubMedGoogle Scholar
  • 48 Girolami A, Morello M, Girolami B, Lombardi AM, Bertolo C. Myocardial infarction and arterial thrombosis in severe (homozygous) FXII deficiency: no apparent causative relation. Clin Appl Thromb Hemost 2005; 11 (1) 49-53
    CrossrefPubMedGoogle Scholar
  • 49 Kelleher CC, Mitropoulos KA, Imeson J , et al. Hageman factor and risk of myocardial infarction in middle-aged men. Atherosclerosis 1992; 97 (1) 67-73
    CrossrefPubMedGoogle Scholar
  • 50 Lowe GDO, Rumley A, McMahon AD, Ford I, O'Reilly DS, Packard CJ ; West of Scotland Coronary Prevention Study Group. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24 (8) 1529-1534
    CrossrefPubMedGoogle Scholar
  • 51 Miller GJ, Esnouf MP, Burgess AI, Cooper JA, Mitchell JP. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler Thromb Vasc Biol 1997; 17 (10) 2103-2106
    CrossrefPubMedGoogle Scholar
  • 52 Grundt H, Nilsen DW, Hetland Ø, Valente E, Fagertun HE. Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. Am Heart J 2004; 147 (2) 260-266
    CrossrefPubMedGoogle Scholar
  • 53 Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood 2006; 108 (13) 4045-4051
    CrossrefPubMedGoogle Scholar
  • 54 Bach J, Endler G, Winkelmann BR , et al. Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. J Thromb Haemost 2008; 6 (2) 291-296
    CrossrefPubMedGoogle Scholar
  • 55 Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C. Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost 2007; 5 (6) 1143-1148
    CrossrefPubMedGoogle Scholar
  • 56 Gailani D, Renné T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007; 27 (12) 2507-2513
    CrossrefPubMedGoogle Scholar
  • 57 Iwaki T, Cruz-Topete D, Castellino FJ. A complete factor XII deficiency does not affect coagulopathy, inflammatory responses, and lethality, but attenuates early hypotension in endotoxemic mice. J Thromb Haemost 2008; 6 (11) 1993-1995
    CrossrefPubMedGoogle Scholar
  • 58 Favaloro EJ, Lippi G. Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. Semin Thromb Hemost 2015; 41 (2) 208-227
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Lippi G, Favaloro EJ. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?. Clin Chem Lab Med 2015; 53 (2) 185-197
    PubMedGoogle Scholar
  • 60 Mackman N. New targets for atherothrombosis. Arterioscler Thromb Vasc Biol 2014; 34 (8) 1607-1608
    CrossrefPubMedGoogle Scholar